Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vusolimogene Oderparepvec · Tudriqev, VO

Oncolytic virus · Kills target cells · developed by Replimune

Approved FDA, Aug 2026
REPL Developer
5 Registered trials

What is Vusolimogene Oderparepvec?

Vusolimogene oderparepvec is a genetically modified herpes simplex type 1 (HSV-1) oncolytic virus that infects and replicates in tumor cells, causing their lysis and releasing tumor-associated antigens that stimulate an anti-tumor immune response. It is studied in cutaneous squamous cell carcinoma, Merkel cell carcinoma, basal cell carcinoma, melanoma and angiosarcoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tudriqev, VO, RP1
Drug type
Oncolytic virus
Mechanism
Kills target cells
Pathways
immune activation, tumor cell lysis
Therapy area
Oncology
Developer
Replimune, Inc. (REPL)
FDA status
Approved as Tudriqev (August 6, 2026), BLA125827
UNII
45KLN7N6UV

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06264180 Phase 3 Advanced Melanoma Recruiting REPL
NCT06898970 Phase 2 Angiosarcoma Recruiting REPL
NCT04349436 Phase 1/2 Merkel Cell Carcinoma Active not recruiting REPL
NCT04050436 Phase 2 Cutaneous Squamous Cell Carcinoma Active not recruiting REPL
NCT06216938 Early Phase 1 Melanoma Recruiting REPL

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Cutaneous Squamous Cell CarcinomaAdvanced MelanomaAngiosarcomaAngiosarcoma, AdultBasal Cell CarcinomaCancerCutaneous Squamous Cell CarcinomaLocally Advanced Cutaneous Squamous Cell CarcinomaMelanomaMerkel Cell CarcinomaMetastatic Cutaneous Squamous Cell Carcinoma

More from Replimune

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the REPL page.

Follow REPL, the company behind Vusolimogene Oderparepvec

See REPL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

REPL catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.